2021;70(Supplement 1):86-LB
Wegovy (semaglutide) is a GLP-1 receptor agonist licensed in the UK for weight management in adults with obesity or overweight with comorbidities
We reported estimates for selected ages (18, 25, 35, 45, 55, 65, and 75) and AUDIT-C scores (0, 3, 5, 8, 11) as an illustrative example of differences across ages and levels of alcohol consumption
can accelerate and amplify the results
Self-reported customer outcomes are not independently verified and should not be interpreted as typical or guaranteed
Keep your doctor in the loop about side effects, theyre the ones who manage medication decisions, not your trainer